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Abstract
CD8
+ T cells provide broad immunity to viruses, because they are able to recognize all types of viral proteins. Therefore, the
development of vaccines capable of inducing long-lived memory CD8
+ T cells is desired to prevent diseases, especially
those for which no vaccines currently exist. However, in designing CD8
+ T cell vaccines, the role of CD4
+ T cells in the
induction and maintenance of memory CD8
+ T cells remains uncertain. In the present study, the necessity or not of CD4
+ T
cells in the induction and maintenance of memory CD8
+ T cells was investigated in mice immunized with liposome-coupled
CTL epitope peptides. When OVA-derived CTL epitope peptides were chemically coupled to the surfaces of liposomes and
inoculated into mice, both primary and secondary CTL responses were successfully induced. The results were further
confirmed in CD4
+ T cell-eliminated mice, suggesting that CD4
+ T cells were not required for the generation of memory
CD8
+ T cells in the case of immunization with liposome-coupled peptides. Thus, surface-linked liposomal antigens, capable
of inducing long-lived memory CD8
+ T cells without the contribution of CD4
+ T cells, might be applicable for the
development of vaccines to prevent viral infection, especially for those viruses that evade humoral immunity by varying
their surface proteins, such as influenza viruses, HIV, HCV, SARS coronaviruses, and Ebola viruses.
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Introduction
It has been reported by numerous investigators that CD4
+ T
cells are essential for the maintenance of memory CD8
+ T cells [1–
5]. However, in the induction and maintenance of CD8
+ memory
T cells, different roles of CD4
+ T cells have been described [6–9].
In the so-called ‘‘classical model’’, CD4
+ T cells contribute to
memory CD8
+ T-cell generation indirectly via APCs [6]. Through
the CD40-CD40L interaction between CD40L on CD4
+ T cells
and CD40 on APCs, CD4
+ T cells ‘‘license’’ APCs for the
induction of memory CD8
+ T cells. As an alternative to this APC
licensing model, Bourgeois et al. [7] provided evidence demon-
strating that CD4
+ T cells contribute directly to CD8
+ T cells
through CD40 on CD8
+ T cells, rather than indirectly via APCs.
However, these findings were countered by studies in which long-
lived CD8
+ memory T cells were generated in the absence of
CD40 expression on CD8
+ T cells [8,9]. In addition, as for the role
of CD40-CD40L interaction in the induction of memory CD8
+ T
cells, Hernandez et al. [10] reported that CD8
+ T cells themselves
provided CD40L in order to license APCs for the induction of
memory CD8
+ T cells. In their scenario, although the CD40-
CD40L interaction between T cells and DCs is indispensable for
the induction of memory CD8
+ T cells, CD4
+ T cells are not
necessarily involved. Thus, the research so far has not resolved the
role of CD4
+ T cells in the induction and maintenance of memory
CD8
+ T cells, although resolving this issue is a critical step in
designing better vaccination and immunotherapeutic strategies.
Upon natural infection, the host responds by inducing humoral
and cellular immunity against the pathogen. Humoral immune
responses are represented by the production of antibodies that
bind to the surfaces of bacteria and viruses, whereas cellular
immune responses mediate immunity to intracellular pathogens.
In general, extracellular antigens are presented via MHC class II
molecules to CD4
+ T cells, whereas intracellular antigens are
presented via MHC class I molecules to CD8
+ T cells. To induce
antigen-specific CTL, antigens must be loaded onto the class I
MHC processing pathway in APCs via cross-presentation [11]. In
the cross-presentation, exogenous proteins cross over to the
endogenous pathway to gain access to MHC class I molecules.
Using this phenomenon, a generation of antigen-specific CTL
responses might be useful in the development of vaccines that can
prevent viral diseases. However, the currently approved alum
adjuvant, which was first described by Glenny et al. [12] in 1926
and until today remains the only adjuvant approved for clinical
use, is known to be effective only for the induction of humoral
immunity, not for the induction of cell-mediated immunity [13–
16]. Consequently, the development of a novel vaccine adjuvant is
essential for the induction of cell-mediated immunity.
We previously reported that surface-coupled liposomal antigens
could be presented by APCs to CD8
+ T cells via MHC class I
molecules if certain lipid components were chosen for the
liposomes [17]. This antigen preparation was expected to be
applicable for the development of tumor vaccines to induce
antitumor responses and for the development of viral vaccines to
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15091induce virus-specific CTLs that effectively eliminate virus-infected
cells [18]. Since the liposomal conjugates induced CTLs efficiently
when CTL epitope peptides were coupled to the surfaces of
liposomes [17], the liposomal conjugatesare expected to be
applicable for the development of CTL-based peptide vaccines.
In the development of peptide vaccines, it is essential to know
whether a T helper epitope peptide is necessary for the induction
of long-lived memory CD8
+ T cells, an important step in vaccine
preparation. This study was aimed at evaluating the role of CD4
+
T cells in the induction of long-lived memory CD8
+ T cells by
liposome-coupled peptides.
Results
Induction of antigen-specific primary CD8
+ T cells and
CTLs in mice by OVA257-264-liposome conjugates
Mice were immunized with OVA257-264-liposome conjugates in
the presence of CpG as described in Materials and Methods. A
significant induction of CTL specific for OVA257-264 was observed
on day 4 and a complete cell killing was observed as early as 5 days
after the immunization (Figure 1). Therefore, in the following
experiments, primary CTL responses were monitored at 7 days
afterimmunization.Micewerethenimmunizedwithseriallydiluted
solution of OVA257-264-liposome conjugates containing 0.3 (86)t o
2.4 mg( 1 6) of peptides or OVA257-264 solution that contained equal
amounts of peptides as those in liposomal conjugates. Although
OVA257-264-liposome and OVA257-264 solution seemed to induce a
comparable level of T-cell cytokine production at the highest dose
(2.4 mg/injection), a dose-dependent decrease was observed in mice
immunized with OVA257-264 solution but not in mice immunized
with OVA257-264-liposome, suggesting that OVA257-264-liposome
was more effective than OVA257-264 solution in the induction of
antigen-specific CD8
+ T cell cytokine production (Figure 2A).
Similar results were observed in T cell cytokine production; a dose
of OVA257-264-liposome as low as 0.6 mg/mouse (46 dilution)
induced a perfect killing as assayed by in vivo CTL assay, while
OVA257-264 solution induced only a partial killing even at the
highest dose (Figure 2B).
Secondary CTL response in mice immunized with
OVA257-264-liposome
Induction of secondary CTL responses in mice immunized with
OVA257-264-liposome was further investigated. Mice were immu-
nized with 50 ml of OVA257-264-liposome and 2, 4, 8, 16, and 20
Figure 1. Kinetics of primary CTL response induced by OVA257-264-liposome conjugates. Mice were immunized with 50 ml of OVA257-264-
liposome in the presence of 5 mg CpG; one to 5 days later, an in vivo CTL assay was performed as described in Materials and Methods. The numbers
for each time period indicate percentages of target cells killed. Data are representative of three individual mice in each group for which similar results
were obtained.
doi:10.1371/journal.pone.0015091.g001
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Three days after the booster injection, OVA257-264-specific cell
killing was monitored. As shown in Figure 3, a complete cell killing
was observed at 2 weeks after the immunization without a booster
injection and, up to 20 weeks after the immunization, a significant
recall response was observed upon booster injection with OVA.
Inoculation of naive mice with the same dose of OVA as the
booster injection (‘‘No imm.’’ in Figure 3) did not induce a
detectable CTL response. Interestingly, a significant recall
response was observed even at 20 weeks when the primary CTL
response was nearly undetectable. An antigen-specific CD8
+ T-cell
proliferation assay further confirmed the results; as shown in
Figure 4, CD8
+ T cells of mice immunized with OVA257-264-
liposome significantly proliferated upon in vitro stimulation with
OVA even 20 weeks after immunization.
Effect of in vivo elimination with CD4
+ T cells on the
induction of long-lived memory CD8
+ T cells by
OVA257-264-liposome conjugates
To eliminate CD4
+ T cells, mice were inoculated with GK1.5 as
described in Materials and Methods, and immunized with
OVA257-264-liposome. As shown in Figure 5, in vivo elimination
with CD4
+ T cells affected neither for primary (Figure 5A) nor for
secondary (Figure 5B) CTL responses; even at 20 weeks after the
immunization, a significant recall response, comparable to that in
normal mice, was observed in mice from which CD4
+ T cells had
been eliminated.
Discussion
In the present study, the role of CD4
+ T cells in the induction
and maintenance of memory CD8
+ T cells was evaluated in mice
immunized with liposome-coupled CTL epitope peptides. Al-
though the inclusion of CpG, a ligand of TLR-9, was needed for
the induction of the primary CTL response by OVA257-264-
liposome, CD4
+ T cells were not required in either primary or
secondary response, since long-lived memory CD8
+ T cells were
readily induced only by immunization with CTL epitope peptides
coupled to liposomes (Figures 3 and 4). This finding was further
confirmed in CD4
+ T cell-depleted mice (Figure 5). These results
are in agreement with those reported previously by numerous
investigators that CD4
+ T cells are dispensable for the primary
expansion of CD8
+ T cells and their differentiation into cytotoxic
Figure 2. Dose-response of cytokine production by CD8
+ T cell and CTL induction in mice immunized with OVA257-264-liposome or
with OVA257-264 solution. A serial two-fold dilution of OVA257-264-liposome (open box) and OVA257-264 solution (closed box) were made in PBS, and
mice were immunized with the diluents in the presence of 5 mg CpG. OVA257-264 solution containing equal amounts of peptides as those in OVA257-
264-liposome. One week after the immunization, IFN-c production by CD8
+ T cells (A) and the CTL response (B) were monitored as described in
Materials and Methods. Data represent means and SE of three mice per group. *, significant difference (p.0.01).
doi:10.1371/journal.pone.0015091.g002
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that secondary CTL expansion is wholly dependent on the
presence of T helper cells during, but not after, priming [1–5].
We previously reported that surface-linked liposomal antigens
induced IgE-selective unresponsiveness [19]. The results were
consistent even when different coupling procedures for the
antigens with the liposomes were employed [20]. During the
course of an investigation intended to clarify the mechanism of
IgE-selective unresponsiveness induced by surface-coupled liposo-
mal antigens, we discovered an alternative approach to regulating
the production of IgE, one that is independent of the activity of T
cells [21]. Immunization of mice with OVA-liposome conjugates
induced IgE-selective unresponsiveness without apparent Th1
polarization. Neither interleukin-12 (IL-12), IL-10, nor CD8
+ T
cells participated in the regulation. Further, CD4
+ T cells of mice
immunized with OVA-liposome were capable of inducing antigen-
specific IgE synthesis in athymic nude mice immunized with alum-
adsorbed OVA. On the other hand, immunization of the recipient
mice with OVA-liposome did not induce anti-OVA IgE
production, even when CD4
+ T cells of mice immunized with
alum-adsorbed OVA were transferred. In the secondary immune
response, OVA-liposomes enhanced anti-OVA IgG antibody
production but did not enhance ongoing IgE production,
suggesting that the IgE-selective unresponsiveness induced by the
liposomal antigen involved direct effects on IgE but not IgG
switching in vivo. These results suggest the role of an alternative
mechanism, one not involving T cells, in the regulation of IgE
synthesis, and raise the possibility that the surface-linked liposomal
antigens are potentially applicable for the development of novel
vaccines with minimal induction of IgE synthesis. Moreover, given
the relatively low allergic response to and increased antigenicity of
the allergen, this form of antigen preparation would be applicable
for allergen immunotherapy [22].
Figure 3. Secondary CTL response in mice immunized with OVA257-264-liposome. Mice were immunized with 50 ml of OVA257-264-liposome
in the presence of 5 mg CpG, and 2, 4, 8, 16, and 20 weeks later, they received a booster ip injection with 200 ml of 1 mg/ml OVA in PBS (closed box)
or no booster injection (open box). Three days after the booster injection, in vivo CTL assay was performed. Data represent mean percentages of cells
killed and SEs of three mice per group. ND, not detected. *, significant difference (p.0.01).
doi:10.1371/journal.pone.0015091.g003
Figure 4. Antigen-specific CD8
+ T-cell proliferation assay. Mice
were immunized with OVA257-264-liposome and 1 week or 20 weeks
later, CD8
+ T cells of the immunized mice were cultured in the presence
(closed box) or absence (open box) of OVA as described in Materials
and Methods. Data represents mean
3H- thymidine incorporation and
SE of triplicate cultures. *, significant difference (p.0.01).
doi:10.1371/journal.pone.0015091.g004
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application to vaccine development was further investigated.
During the course of this investigation, a significant difference was
observed in the recognition of liposomal antigens by antigen-
presenting cells (APCs) between liposomes with different lipid
components [23], and this difference was closely correlated with
the adjuvant activity of liposomes [24]. In addition to this
‘‘quantitative’’ difference between liposomes with different lipid
components, a ‘‘qualitative’’ difference (i.e., different abilities to
induce cross-presentation) was also observed between liposomes
with different lipid components [17]. Although the precise
mechanism underlying this difference is currently unclear, the
significant difference in membrane mobility observed between
these liposomes [24] might affect their ability to induce cross-
presentation. Thus, by utilizing their ability to induce cross-
presentation, surface-linked liposomal antigens could be used to
develop virus vaccines that induce a cytotoxic T-cell (CTL)
response, as well as tumor vaccine preparations that present tumor
antigens to APCs and induce effective antitumor responses [18].
Regarding the necessity of CD4
+ T cells in the generation of
memory CD8
+ T cells, the results of the present study differed
from those reported previously [1-5]. The difference in these
findings may be due to differences in how mice were primed with
antigens; in most of the studies reported previously, mice were
primed by infecting viruses, such as LCMV [1,3,5], H3N2
influenza virus [2], and recombinant vaccinia virus [4], whereas in
the present study, mice were immunized with OVA-derived CTL
epitope peptides. Perhaps the difference in the requirements of
CD4
+ T cells observed among those studies [1–5] and the present
study was due to the difference in the efficiency of inducing the
presentation of the immunodominant CTL epitope by APCs. In
general, only ,1/2000 of the peptides in a foreign antigen
expressed by an appropriate APC achieve immunodominant
status with a given class I allele [25]. However, in the present
study, immunization with OVA257-264-liposome successfully in-
duced both primary and secondary CTL responses without the
presence of CD4
+ T cells (Figures 2 to 5). In addition, it was
reported previously that antigens coupled to the surface of
liposomes are recognized effectively by APCs and presented to
T cells [24]. Therefore, although the TLR-ligand (CpG, in the
present study) was necessary to mimic viral infection in order to
induce CTL responses in the immunization with liposome-coupled
peptides, CD4
+ T cells were not required for the induction and
maintenance of CD8
+ memory T cells.
There is considerable interest in developing vaccines that elicit
effective antiviral CD8
+ T cell responses [26] against a variety of
viruses, such as HIV [27], HCV [28], and SARS coronavirus [29].
For this purpose, the utilization of the immunodominant CTL
epitope would be more effective than the use of an attenuated,
inactivated, or subunit vaccine in the development of virus
vaccines to elicit effective antiviral CD8
+ T cell responses. For
example, although the risk of a major global pandemic of avian
influenza has created widespread concern, vaccines designed to
induce antibodies against H5 haemagglutinin are expected to
possess little or no efficacy, given the high rate of diversification of
H5N1 strains due to the antigenic drift caused by point mutation
of genes [30–33]. On the other hand, it is known that cytotoxic T
cells specific for the internal proteins NP and M1 show high cross-
reactivity between strains and between subtypes, reflecting high
conservation of the internal proteins [34–37]. In addition, Lee et
al. [38] recently reported that people who have not been exposed
to H5N1 viruses have cross-reactive CD8
+ T cell memory to a
wide range of H5N1 peptides. Therefore, these peptides are
expected to be used to add a CD8
+ T cell component to current
antibody-focused vaccine strategies with a view to reducing the
impact of infection with novel influenza A viruses [39]. Epstein et
al. [40] studied DNA vaccination in mice with plasmids expressing
conserved nucleoprotein (NP) and matrix (M) from an H1N1
virus. However, the DNA vaccination alone protected poorly
against a highly virulent strain of H5N1 influenza viruses.
Recently, we reported that peptides derived from the internal
NP protein of the H3N2 influenza virus, chemically coupled to the
surface of liposomes, induced antigen-specific CTLs and success-
fully inhibited the growth of H3N2 influenza virus in the lung [41].
More recently, we determined human HLA class I-restricted,
immunodominant CTL epitopes derived from internal proteins of
H5N1 influenza viruses [42]. Similar to those results reported
previously [34–37,43], most of the CTL epitopes determined were
well conserved and were identical with those involved in H1N1
and H3N2 influenza viruses. The combined use of these CTL
epitope peptides, common to influenza viruses, and the surface-
linked liposomal antigens which induce long-lived memory CD8
+
T cells without CD4
+ T cell help, was demonstrated to be
Figure 5. Effect of in vivo elimination of CD4
+ T cells on
the induction of primary and secondary CTL responses by
OVA257-264-liposomes. Mice with (closed box) or without (open box)
CD4
+ T-cell elimination were immunized with 50 ml of OVA257-264-
liposome solution in the presence of 5 mg CpG, and CTL induction was
monitored. A, CTL response 1 week after immunization. B, CTL
response 20 weeks after immunization with or without booster
injection. In vivo CTL assay was performed 3 days after the booster
injection. Data represent mean percent killing and SE of three mice per
group. ND, not detected. *, significant difference (p.0.01).
doi:10.1371/journal.pone.0015091.g005
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that is capable of inducing protection against heterosubtypic
influenza viruses [42].
Taken together, these results suggest that surface-linked
liposomal antigens might be applicable for the development of
CTL-based vaccines to induce long-term prevention against
infection with viruses other than influenza viruses, especially for
those viruses that evade humoral immunity by varying their
surface proteins, such as HIV, HCV, and SARS coronaviruses.
Materials and Methods
Mice
CBF1 mice (5–6 wk of age) were purchased from SLC
(Shizuoka, Japan). All mice were maintained under specific
pathogen-free conditions. Experiments in the present study were
approved (permit numbers 208021 and 209082) by the Animal
Research Committee of National Institute of Infectious Diseases,
Tokyo, Japan and the mice were handled according to
international guidelines for experiments with animals.
Chemicals
All phospholipids were obtained from NOF Co. (Tokyo, Japan).
Reagent grades of cholesterol were purchased from Wako Pure
Chemicals (Osaka, Japan).
Antigens and Reagents
Ovalbumin (OVA, grade VII) was purchased from Sigma-
Aldrich. Mouse MHC class-I (K
b)-binding peptides OVA257-264
(SIINFEKL) were obtained from Operon Biotechnologies (Tokyo,
Japan). Synthetic CpG ODN (5002: TCCATGACGTTCTT-
GATGTT), phosphorothioate-protected to avoid nuclease-depen-
dent degradation, was purchased from Invitrogen.
Liposomes
The liposomes used in this study are provided by NOF
corporation (Tokyo, Japan). They consisted of dioleoyl phosphati-
dylcholine (DOPC), dioleoyl phosphatidyl ethanolamine (DOPE),
dioleoyl phosphatidyl glycerol (DOPG), and cholesterol in a 4:3:2:7
molar ratio. The crude liposome solution was passed through a
membrane filter (Nucleopore polycarbonate filter; Coster) with a
pore size of 0.2 mm.
Coupling of OVA peptides to liposomes
Liposomal conjugates with OVA peptides were prepared
essentially in the same way as described previously [17] via
disuccinimidyl suberate (DSS). Briefly, a mixture of 10 ml of
anhydrous chloroform solution containing 0.136 mM DOPE and
24 ml of TEA was added in drops to 26.6 ml of anhydrous
chloroform solution containing 0.681 mM DSS and stirred for 5 h
at 40uC. The solvent was evaporated under reduced pressure, and
18 ml of a 2:1 mixture of ethyl acetate and tetrahydrofuran was
added to dissolve the residue. Then, 36 ml of 100-mM sodium
phosphate (pH 5.5) and 90 ml of saturated NaCl aqueous solution
were added to the solution, shaken for 1 min, and allowed to
separate. To remove undesirable materials, the upper layer was
washed with the same buffer and, after evaporation of the solvent,
3 ml of acetone was added to dissolve the residue. One hundred ml
of ice-cold acetone was added in drops and kept on ice for 30 min
to precipitate. Crystals were collected and dissolved in 5 ml of
chloroform. After evaporation, 34.4 mg of DOPE-DSS was
obtained. Then, 0.18 mM DOPC, 0.03 mM DOPE-DSS,
0.21 mM cholesterol, and 0.06 mM DOPG were dissolved in
10 ml of chloroform/methanol. The solvent was removed under
reduced pressureand5.8 mlofphosphate buffer(pH 7.2) was added
tomakea4.8%lipidsuspension.Thevesicledispersionwasextruded
through a 0.2-mm polycarbonate filter to adjust the liposome size. A
2-mlsuspensionofDSS-introducedliposomeand0.5 mlof5-mg/ml
OVA peptide solution were mixed and stirred for 3 days at 4uC. The
liposome-coupled- and uncoupled peptides were separated as
described above using CL-4B column chromatography. The
resulting solution of OVA257-264-liposome conjugates contained
47 mg/ml of peptides as assessed by amino-acid quantitative analysis
done by Toray Research Center (Kanagawa, Japan).
Immunization
All the mice were immunized with indicated doses of
OVA257-264-liposome conjugates via subctaneous injection in the
presence of 5 mg/mouse CpG. For the booster immunization, the
mice were immunized intraperitoneally (ip) with 200 ml of 1-mg/
ml OVA in PBS solution.
In vivo elimination of CD4
+ T cells
For the in vivo elimination of CD4
+ T cells, mice received weekly
ip injection with 0.5 mg of GK1.5, a monoclonal anti-CD4
antibody, throughout the experimental period. This treatment
resulted in a .99% decrease in the number of CD4
+ T cells in the
spleen and lymph nodes as determined by fluorescence-activated
cell sorter (FACS) analysis.
In vivo cytotoxicity assay
Spleen cells of naive CBF1 mice were labeled with either
0.5 mM (dull) or 5 mM (bright) CFSE for 15 min at 37uC using a
Cell Trace CFSE cell proliferation kit (Molecular Probes, Eugene,
OR) and washed twice with ice-cold PBS. CFSE-bright cells were
subsequently pulsed with 0.5 mg/ml of OVA257-264 for 90 min at
37uC. CFSE-bright cells and CFSE-dull cells were mixed at a 1:1
ratio, and then a total of 1610
6 cells was injected i.v. into the
indicated group of mice. Twenty hours later, spleen cells were
harvested from each mouse and analyzed by using FACSCalibur
(Becton Dickinson, Mountain View, CA).
Cell culture
All incubations were performed in RPMI-1640 (Invitrogen Life
Technologies) supplemented with 10% heat-inactivated FCS
(HyClone), 100 U/ml penicillin, and 100 mg/ml streptomycin
(Invitrogen).
Preparation of dendritic cells (DC) and CD8
+ T cells
DCs and CD8
+ T cells were obtained from spleen cells of CBF1
mice using the magnetic cell sorter system MACS according to the
manufacturer’s protocol using anti-CD11c and anti-CD8 anti-
body-coated microbeads (Miltenyi Biotec), respectively. CD8
+ T
cells and DCs were suspended in RPMI-1640 containing 10%
FCS at cell densities of 2610
6/ml and 8610
5/ml, respectively.
The CD8
+ T cell suspension was plated at 250 ml per well onto 48-
well culture plates (No. 3047; BD Biosciences), and 250 mlo fD C
suspension and 500 mlo f4 0mM OVA257-264 solution in the same
medium were added to the plates. After incubation in a CO2
incubator for 5 days, the culture supernatants were collected and
assayed for the concentration of IFN-c.
Cytokine assays
IFN-c in the culture supernatant was measured using the
Biotrak mouse ELISA system (GE Healthcare, UK). All test
samples were assayed in duplicate, and the SE in each test was
always less than 5% of the mean value.
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Splenic CD8
+ T cells (5610
5 cells/well) of immunized mice and
whole spleen cells (1610
5 cells/well) of 25 Gy-irradiated naı ¨ve
mice were cultured in 96-well plates for 4 days in the presence
(closed box) or absence (open box) of 20 mM OVA. The cells were
pulsed with 1.25 mCi (0.046 MBq) [
3H]-thymidine (PerkinElmer)
for the final 6 hours of the culture, and, after harvesting, cell
proliferation was monitored using TopCount (PerkinElmer).
Statistical analysis
Student’s t test was employed for the statistical analysis.
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